



همایش سراسری انجمن خون و سرطان کودکان ایران
با موضوع بیماریهای گلبول سفید در کودکان

چهاردهمین

۲۷ - ۲۸ بهمن ماه ۱۴۰۱
(تهران - هتل بزرگ ارم - سالن سپهر)

14th

Annual Congress of Iranian Pediatric Hematology & Oncology Society

White Blood Cell Disorders in Children

16-17 Feb 2023 (Hotel ERAM, Tehran)



موسسه نیکوکاری کنترل سرطان ایران

مکس





مركز کنترل سرطان ایران



مركز کنترل سرطان ایران

اهداف برنامه:

نوتروپنی - لنفوسیتوز
پیوند سلول های بنیادی - نقش سلول های NK
تب و نقایص ایمنی اولیه
بازوفیلی - مونوسیتوز
اُتوزینوفیلی - لنفوپنی



Aburaihan
Pharma

ARYOGEN
آریوژن فارمد

Baxter

رونک
شرکت داروسازی

دوسان
دارو


شرکت سامان دارویی ششم

شرکت داروسازی آوینا
Avicenna
Pharmaceuticals Inc.

فدایا
شرکت داروسازی



شناسه بازآموزی
۱۹۰۳۰۴




Neutrpenia & factor 7 deficiency

دکتر بابک عبدالکریمی
هماتولوژیست آنکولوژیست کودکان
دانشگاه علوم پزشکی لرستان

Case presentation:

- A 10 y boy with severe neutropenia(resolve by GCSF) and recurrent bleeding tendency(factor 7=37%)
- +Osteopenia(causes recurrent pathologic FX in long bones)



آزمایشگاه تشخیص طبی سیمرغ
میدان انقلاب اسلامی - خ کارگر شمالی - خ نصرت غربی - پلاک ۳۷
تلفن: ۴۰۶۶۱۰۴۵

شماره پذیرش: ۱۲-۳۶
تاریخ پذیرش: ۱۴۰۰/۱۲/۰۱
نام مراجعه کننده: آقای محمدامید عبدالله زاده
سن: ۱۳ سال
پزشک معالج: دکتر لیلای مرادی

Hematology

Test	Result	Unit	Reference Range	Differential
Complete Blood Count				
W.B.C	L 2.95	$\times 10^3/\text{micL}$	3.9 - 11.5	Neutrophils (L) 6 %
R.B.C	H 5.39	$\times 10^6/\text{micL}$	3.9 - 5.3	Lymphocyte (H) 79 %
Hemoglobin	15.2	$\times 10^3/\text{micL}$	12.8 - 16	Monocyte (H) 15 %
Hematocrit	44.4	$\times 10^3/\text{micL}$	37 - 46	
M.C.V	82.4	fL	77 - 92	
M.C.H	28.2	pg	25 - 34	
M.C.H.C	34.2	g/dL	34.2 - 35.7	
Platelet Count	197	$\times 10^3/\text{micL}$	170 - 450	
RDW-CV	13.7		13 - 15.5	

Reference ranges are according to the age and sex of the patient.

Checked by:

راهنمایی مسئول فنی برای پزشک و بیمار:

Lab Director: Dr. T. Ghazanfari Dr. A. Jelveh



NOOR Pathology Lab

Dr. A. Alizadeh MD AP-CP

آزمایشگاه باتوبیولوژی نور

انجام آزمایشات تشخیصی پزشکی - باتوبیولوژی و سیتوپاتولوژی



دکتر اصغر علیپور - مسئول فنی آزمایشگاه باتوبیولوژی

شماره پذیرش: ۱۲-۱۸۲۵
تاریخ پذیرش: ۱۳۹۴/۱۲/۰۹
تاریخ جوابدهی: ۱۳۹۴/۱۲/۱۷
پزشک معالج: آقای دکتر بابک عبدالکریمی
نام مراجعه کننده: آقای محمدامید عبدالله زاده
سن: ۷ سال
شماره باتوبیولوژی: P-94-19094

SPECIMEN : Bone marrow biopsy & Aspiration

CLINICAL DATA : Neutropenia

GROSS DESCRIPTION:

Received specimen in formalin in one container labeled as " BMB " consists of 0.5 cm needle shaped bone tissue with 5 aspiration slides & 2 PBS.

MICROSCOPIC DESCRIPTION:

PERIPHERAL BLOOD:

RBC Morphology: Mild aniso-poikilocytosis
WBC: Neutr: 3%, Lymph: 92%, Mono: 5%
Plt: Mild decreased

BONE MARROW ASPIRATION:

There are numerous hematopoietic cells in different stages of maturation. The erythroid series are prominent. The myeloid series shows decrease maturation.

TREPHINE BONE BIOPSY:

Section shows fragment of bone marrow and intertrabecular marrow spaces. The intertrabecular spaces containing polymorphic marrow population with about 80% cellularity. The myeloid, erythroid, lymphoid and megakaryocytic series are present. The erythroid series are prominent. The myeloid series shows decreased maturation & hypoplasia.

DIAGNOSIS:

Bone marrow aspiration and trephine biopsy:

- Myeloid hypoplasia in marrow & peripheral neutropenia
- Relative erythroid hyperplasia

Note: Both familial abnormalities & acquired disease (such as drug reactions and viral disease) could show above pattern. A constellation of clinical and pathological characteristics is necessary to reach a correct diagnosis.



خرم آباد - پل شهدا - ابتدای کوچه مغایرات تلفن: ۲۲۳۲۹۲۹

IN THE NAME OF GOD
ISFAHAN UNIVERSITY OF MEDICAL SCIENCES
SAYEDAI-SHOHADA HOSPITAL
FLOWCYTOMETRY

NAME: MOHAMMAD OMID
AGE: ABDOLLAHZADEH
SEX: 5
Male
SAMPLE: BMA

PATIENT NO: 92-A-493
DATE: 1392/05/29
VIABILITY: GOOD
Doctor: KARGAR

CYTOCHEMICAL STAINING
MYELOPEROXIDASE:
PERIODIC ACID SHIFF:

	MARKER	Lymph	Gran	Mono	Total
COMMON ALL ANTIGEN	CD10	31%			
PAN B-CELL	CD19	52%			
MONOCYTE/GRANULOCYTE	CD13		39%		
B-CELL	CD20	55%			
LEUKOCYTE COMMON ANTIGEN	CD45	83%			
LEUKOCYTE COMMON ANTIGEN	CD45		76%		
MONOCYTE/GRANULOCYTE	CD33		98%		
HEMATOPOIETIC PRECURSOR CELL	CD34	15%			
STEM CELL FACTOR RECEPTOR	CD117		2.3%		
TERMINAL DESOXYTRANSFERASE	TdT	3%			
MHC Class II	HLA-DR	56%			
ALPHA CHAINE BETA-2 INTEGRINE	CD11b		92%		
LOW EXPRESSION CD45/CD117	CD45/CD117		0.5%		

COMMENTS: BMA immunophenotyping reveals a population of lymphoid cells about 12% which are positive for CD10, CD19, CD20 that are more compatible with hematogones.
Close follow up of the patient is recommended.

مرکز آلودگی محیطی و بهداشتی
دکتر مهرداد جعفری
مهندس کمالی و آلودگی
تلفن: ۵۱۵
پست: ۶۱۴
M. Haidarpour MD. ACP

A. KAZEMI-Technologist
M.Sc of Hematology

Noor Specialized Clinical & Anatomical Lab -
Dr. ASGHAR ALIEPOUR MD AP CP
KHORAMABAD, SHOHADA BRIDGE, MOKHABERAT
STREET - Tel: 33332939 - Fax: 33333814

آزمایشگاه تخصصی تشخیص پزشکی و پاتولوژی نور
دکتر اصغرعلیه پورمتخصص پاتولوژی آناتومیال و کلینیکال
خرم آباد: پل شهید، ابتدای کوچه مخابرات تلفن: ۳۳۳۳۲۹۳۹
فکس: ۳۳۳۳۳۸۱۴

س ۱۳۹۲

تاریخ پذیرش: ۱۳۹۲/۱۲/۰۹ پزشک معالج:

سن: ۷ سال

شماره پذیرش: ۱۲-۱۸۲۹
نام مراجعه کننده: آقای محمدامید عبدالله زاده

Hematology2

Test	Result	Unit	Normal Range
CD10	12		
CD45	96		
CD33	10		
CD34	<1		
CD13	3		

Comment:

Please see the attached file for details

DR. Aliepour MD. AP CP



CD117 (P-glycoprotein)	12	CD19 (Pan-B)	26	CD10 (CALLA)	12
Stem-Cell Associated Markers	%	Comments	%	Comments	%
B-Cell Associated Markers	%	Comments	%	Comments	%

Interpretation / Diagnosis: Markedly diluted / Hypocellular marrow, immunophenotyping & cytomorphology results with flow cytometry for B-cell lineage (CD19, CD10, CD13, CD20, CD45) should be considered.

Specimen ID: P94-1850	Collected: Clinic	Age: 7 years	Physician: Noor Lab
Received date: 10.12.94	Medi Code:	Specialty: Referral Lab	
Report date: 10.12.94	Phone #:	Source of Tissue/Specimen:	Bone Marrow
		Viability: >90%	

With Quality Certificate Awarded by Health Reference Laboratory
Ministry of Health and Medical Education



Payvand
Clinical and Specialty Laboratory
No. 174, Zafar St, Shahr-e Agha
Phone: +98 21 2226414-5
Website: www.payvandlab.com
Email: info@payvandlab.com




Lab Ref: PBx10328-1/ 950021201

Reported: 1395/01/25 Object: Blood - Heparin
Received: 1395/01/15 Age: 8 Years
Sex: Male
Clinical Data: Rule in/out Fanconi anemia
First cousin parents

نام: محمد امید عبدالله زاده

پزشک معالج: -



Twenty metaphase spreads were studied from routine culture, 100 spreads from culture prepared with addition of two concentrations of mitomycin C and were compared with 100 spreads from age related normal control. 4 breaks and 1 radial rearrangement were detected in 4 cells in culture of proband, yielding an average of 0.06 breaks per metaphase; while 2 breaks and 1 radial rearrangement (average of 0.04 metaphase) in 3 cells were detected in normal control. From cytogenetic point of view breakage more or equal to 19 fold of control is clinically significant. Analysis at 500-550 band resolution revealed no chromosomal aberration.

Conclusion: 46,XY compatible with apparently normal male from cytogenetic point of view

Comment: Study of chromosome breakage following clastogenic agents has been shown to have false negative and false positive results. The cause of false negative results may be 1. mitoticism as a result of gene reversion and 2. the overlap of breakage range between normal and affected individuals specially when using Mitomycin C. Therefore close correlation with clinical profile is necessary in interpretation of the results.

Subtle genomic changes beyond the technical limits of the preparation and low-level mosaicism are potentially possible in cases with apparently normal karyotype.

Supervisor In Charge

Clinical Advisor

M.H. Karimi Nejad, M.D.
Prof. of Pathology & Genetics

Signature of M.H. Karimi Nejad

خلاصه بررسی ژنتیکی

تاریخ تولد: ۱۳۸۷/۰۸/۱۰

جنسیت: مذکر

نام و نام خانوادگی بررسی شونده: محمد امید عبدالله زاده

تاریخ گزارش: ۱۳۹۷/۱۲/۲۵

تاریخ پذیرش: ۱۳۹۷/۰۸/۲۹

همکار محترم ارجاع دهنده: جناب آقای دکتر عبدالکریمی

بررسی های صورت گرفته:

بررسی کلیه نواحی اگزونی شناخته شده (Whole Exome Sequencing) به روش تعیین توالی لسل دوم (NGS)

خلاصه نتایج و تفسیر:

در بررسی صورت گرفته، نمونه مورد بررسی دارای یک واریانت در یک ژن مرتبط با بیماری های نزدیک به قوتیب ذکر شده توسط پزشک محترم می باشد.

- یک واریانت missense بصورت همزیگوت (با جزئیات ذکر شده در گزارش اصلی) در ژن *WAS* شناسایی گردید. این ژن به عنوان عامل بیماری های *X-linked thrombocytopenia* *Intermittent X-linked severe congenital neutropenia* *Wiskott-Aldrich syndrome* با نوارت وابسته به X مغلوب گزارش شده است. این تغییر ناکتون به عنوان جهش بیماری زا گزارش نشده است. بنابر بررسی های صورت گرفته (شامل فراوانی جمعیتی و آنالیزهای بیوفورماتیک) و بر اساس دستورالعمل ACMG، این تغییر را می توان در گروه *Variant of Uncertain Significance (VUS)* طبقه بندی نمود.

- طبق دستورالعمل های جاری، واریانت های با طبقه بندی VUS را نمی توان مبنای تصمیم گیری های بالینی تشخیصی از جمله تشخیص پیش از تولد قرار داد. طبیعتا بررسی های بیشتر (شامل بررسی این واریانت در سایر افراد خانواده/شجره و مطالعات عملکردی) جهت تعیین دقیق بیماری زا بودن یا نبودن این واریانت ضروری می باشد. در این راستا با در نظر گرفتن نوارت وابسته به X مغلوب بیماری های حاصل از ژن *WAS*، در صورت نقل (هتروزیگوت) بودن مادر برای واریانت فوق، بررسی دایی (ها) و نمونه در دسترس از پدر بزرگ مادری از نظر واریانت فوق، جهت تفسیر دقیقتر واریانت لازم می باشد.

- علاوه بر واریانت فوق، در نمونه مورد بررسی، یک واریانت دیگر به صورت هتروزیگوت در ژن *DHX38* یافت شد. بر اساس دستورالعمل ACMG، این تغییر را می توان در گروه *pathogenic* طبقه بندی نمود. این ژن به عنوان عامل بیماری *Retinitis pigmentosa-84* با نوارت اتوزومی مغلوب گزارش شده است. با توجه به هتروزیگوت بودن محمد امید عبدالله زاده، ایشان به بیماری مذکور مبتلا نمی باشد. ولی بررسی والدین ایشان، جهت تعیین وضعیت آنها برای این واریانت قبل از بارداری بعدی توصیه می گردد. در صورتی که والدین هر دو برای این واریانت یا هرگونه واریانت *pathogenic* یا *likely pathogenic* دیگر در این ژن ناقل باشند، احتمال ۲۵ درصد برای ابتلا فرزند در هر بارداری برای بیماری مذکور را باید مد نظر داشت. همچنین مشاوره ژنتیک و بررسی ناقل بودن احتمالی در برادران و خواهران فرد بیمار، و در صورت تایید ناقل بودن والدین، در برادران و خواهران ایشان نیز توصیه می شود. این بررسی ها باید قبل از بارداری صورت گیرند. طبیعتا اهمیت این امر در صورت ازدواج خویشاوندی در این افراد بیشتر خواهد بود.

- واریانت های گزارش شده، حاصل بررسی به روش NGS بوده است و با روش مولکولی دیگری تایید نشده اند. لذا لازم است نسبت به تایید این واریانت ها با یک روش مولکولی دیگر اقدام شود.
- ضروری است توجه گردد که در این مرحله، امکان انجام تشخیص پیش از تولد برای بیماری فرزند مبتلا، در این خانواده وجود ندارد. لذا توصیه می گردد والدین و سایر افراد در معرض خطر در خانواده/شجره، تا اتمام کامل بررسی های لازم و تعیین تشخیص و جهش (های) عامل، از بارداری پرهیز نمایند.

صفحه ۱ از ۲

نشانی: خیابان کارگر شمالی - بالاتر از تقاطع فاطمی کارگر - نبش کوچه اشراقی - پلاک ۱۳۲۴ - طبقه اول

کد پستی: ۱۴۱۱۸۹۳۴۸۷

تلفن: ۰۲۷۶۸ ۶۶۹۰ ۹۸۲۱

www.watsonlab.ir

04-294
آقای محمد امید عبدالله زاده
سن: 13 سال
تاریخ پذیرش: 1400/04/16 پزشک معالج: آقای دکتر محمد رضا بقایی پور
ضمیمه دکتر سرکار

Coagulation Laboratory (Factor Assay)

Test	Result	Unit	Normal Range
F VII Activity (1-Stage method)	L 37	%	50 - 150

L=Low

M. Jazebi MSc.

مرکز درمان هموفیلی ایران
دکتر حمیدرضا جمالی
Dr. Hamidreza Jamali

دکتر محمد رضا بقایی پور
متخصص کودکان - ن - تهران
شعبه هموفیلی از آنکستان
۱۳۸۷/۲/۱۹

۰۳-۱۰۶
آقای محمد امید عبدالله زاده
سن: ۹ سال
تاریخ پذیرش: ۱۳۹۶/۰۳/۰۶ پزشک معالج: آقای دکتر محمد رضا بقایی پور
اشتراک: ۹۵۸۹۷۳۸۲

Coagulation Laboratory (Factor Assay)

Test	Result	Unit	Normal Range
F VIII Activity (1- Stage method)	98	%	50 - 150
vWF Activity (RiCof method)	89	%	50 - 150
vWF Antigen (Turbidimetric method)	101	%	50 - 150
F IX Activity (1-Stage method)	92	%	50 - 150
F XI Activity (1-Stage method)	98	%	50 - 150
F XII Activity (1-Satge method)	79	%	50 - 150

M. Jazebi MSc.

Dr. Hamidreza Jamali




Key questions about this case:

- 1. what is his diagnosis?
- 2. is WAS correct diagnosis for this patient?
- 3. what cause of osteopenia in this patient?
- 4. what is correlation between factor 7 deficiency and neutropenia?



tissue factor & factor 7

- Tissue factor (TF) is a **transmembrane receptor for Factor VII/VIIa (FVII/VIIa)**.
- TF also called **CD142** or **plt TF** or **coagulation facctor 3**
- It is constitutively expressed by **cells surrounding blood vessels**.
- The endothelium physically separates this potent "activator" from its circulating ligand FVII/FVIIa and prevents inappropriate activation of the clotting cascade.



CASE REPORT

A novel mutation in Wiskott-Aldrich gene manifesting as macrothrombocytopenia and neutropenia

Daniel Lee²,
Abdullah Haddad³,
Prena Mewawalla⁴

Correspondence to Dr Mais Arwani, dr.arwani@gmail.com, mais_arwani@yahoo.com

Summary

Wiskott-Aldrich syndrome (WAS) is a rare X-linked disorder, described as a clinical triad of microthrombocytopenia, eczema and recurrent infections. Different mutations in WAS gene have been identified, resulting in various phenotypes and a broad range of disease severity, ranging from classic WAS to X-linked thrombocytopenia and X-linked neutropenia. WAS in some cases can be fatal without haematopoietic stem cell transplantation early in life. In this particular case, we present a novel mutation with a unique presentation. An 18-year-old man incidentally found to have **macrothrombocytopenia and neutropenia** at 16 years of age later found to be **hemizygous for c. 869T>C (p.Ile290Thr) mutation in WAS gene**. The late presentation, absence of other manifestations of WAS and presence of macrothrombocytopenia, rather than microthrombocytopenia, which is usually a characteristic finding in WAS, misled the initial diagnosis. On review of literature, **this mutation has not been reported as causing WAS.**

<http://dx.doi.org/10.1136/bcr-2018-225123>

X-Linked Neutropenia with a I294T Mutation of the Wiskott-Aldrich Syndrome Gene.


Melanie M. Gotter, MD,

Blood (2006) 108 (11): 1278.

<https://doi.org/10.1182/blood.V108.11.1278.1278>

X-linked neutropenia (XLN, OMIM #300299) is a rare cause of severe congenital neutropenia and was first described in a three-generation Belgian family with 5 affected members. Reported features of XLN include severe congenital neutropenia and monocytopenia with recurrent bacterial infections, a decreased CD4/CD8 ratio and bone marrow maturation arrest at the promyelocyte/metamyelocyte stage. In the Belgian family, a **L270P WAS mutation** was identified, causing constitutive activity of the Wiskott-Aldrich-syndrome protein (WASP) toward actin polymerisation (Devriendt et al. Nat.Genet. 2001). Here, we report the clinical phenotype of a second large family with XLN and with a **I294T WAS mutation**. In this three-generation family, 10 affected males (7–45 y) and 8 female carriers were identified. Variable non-cyclic neutropenia is present in affected males ($0.2\text{--}3.3 \times 10^9/\text{L}$ in those not on G-CSF; $0.1\text{--}1.0 \times 10^9/\text{L}$ on G-CSF). Five of 10 affected males in the I294T family have monocytopenia. A consistent feature in all cases is a reduced NK cell number. In fact, 3 of 3 tested L270P cases also had reduced NK cell counts. The severity of the clinical phenotype is variable without apparent correlation with the degree of neutropenia. Five of 10 affected males are receiving treatment with G-CSF because of recurrent infections. Four of 10 are reported healthy in the absence of G-CSF. One case with a borderline neutrophil count ($2.4 \times 10^9/\text{L}$) is not on G-CSF, despite recurrent infections. In addition, two males with a history of recurrent infections, at least one of whom had neutropenia, died of infectious causes at age 5 and 18 years.



Platelet counts are variably reduced in affected males, but with normal platelet volume. No consistent abnormalities in CD4/CD8 ratio are found. Available bone marrows have revealed no myelodysplastic features or cytogenetic abnormalities. Of note, female carriers show intermediate findings in neutrophil, platelet and NK cell counts. Only 1 female carrier is known with recurrent upper respiratory and ear infections and is treated with G-CSF. The T916C mutation we found in exon 9 of WAS, has recently been described (Ancliff et al. Blood online 2006) and results in a I294T mutation of the WASP GTPase-binding domain (GBD). The I294T GBD-VCA construct has a lower melting temperature (36°C) as measured by circular dichroism spectroscopy (78°C for wild-type). In the absence of Cdc42, I294T GBD-VCA is nearly completely active toward the Arp2/3 complex, contrary to wild-type GBD-VCA, but similar to the L270P construct. Thus, these data provide new and independent genetic evidence that mutations that disrupt the auto-inhibitory domain of WASP are the cause of XLN. In addition, based on this largest XLN kindred to date, reduced NK cell counts appear a consistent feature. None of the affected males presented with myelodysplasia. Finally, female carriers have moderately reduced neutrophil counts, mostly without clinical consequences. Thus, the presence of mild neutropenia in potential female carriers does not rule out the possibility



Tissue factor-positive neutrophils bind to injured endothelial wall and initiate thrombus formation

Roxane Darbousset¹, DOI: [10.1182/blood-2012-06-437772](https://doi.org/10.1182/blood-2012-06-437772)

For a long time, blood coagulation and innate immunity have been viewed as interrelated responses. Recently, the presence of leukocytes at the sites of vessel injury has been described. Here we analyzed **interaction of neutrophils, monocytes, and platelets in thrombus formation** after a laser-induced injury in vivo. Neutrophils immediately adhered to injured vessels, preceding platelets, by binding to the activated endothelium via leukocyte function antigen-1-ICAM-1 interactions. Monocytes rolled on a thrombus 3 to 5 minutes postinjury. The kinetics of thrombus formation and fibrin generation were drastically reduced in low tissue factor (TF) mice whereas the absence of factor XII had no effect. In vitro, TF was detected in neutrophils. In vivo, the inhibition of neutrophil binding to the vessel wall reduced the presence of TF and diminished the generation of fibrin and platelet accumulation. Injection of wild-type neutrophils into low TF mice partially restored the activation of the blood coagulation cascade and accumulation of platelets. Our results show that the interaction of **neutrophils with endothelial cells is a critical step preceding platelet accumulation for initiating arterial thrombosis in injured vessels**. Targeting neutrophils interacting with endothelial cells may constitute an efficient strategy to reduce thrombosis.





The emerging role of neutrophils in thrombosis—the journey of TF through NETs

Konstantinos Kambas, Ioannis Mitroulis and Konstantinos Ritis*

First Department of Internal Medicine, University General Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece

Edited by:

Marko Radic, University of
Tennessee, USA

Reviewed by:

A. Phillip Owens III, University of
North Carolina at Chapel Hill, USA
Guillermina Girardi, University
of Edinburgh, UK

***Correspondence:**


Konstantinos Ritis, First Department
of Internal Medicine, University
General Hospital of Alexandroupolis,
Democritus University of Thrace,
Dragana, Alexandroupolis, Greece.
e-mail: ritis2@otenet.gr

The production of TF by neutrophils and their contribution in thrombosis was until recently a matter of scientific debate. Experimental data suggested the *de novo* TF production by neutrophils under inflammatory stimuli, while others proposed that these cells acquired microparticle-derived TF. Recent experimental evidence revealed the critical role of neutrophils in thrombotic events. Neutrophil derived TF has been implicated in this process in several human and animal models. Additionally, neutrophil extracellular trap (NET) release has emerged as a major contributor in neutrophil-driven thrombogenicity in disease models including sepsis, deep venous thrombosis, and malignancy. It is suggested that NETs provide the scaffold for fibrin deposition and platelet entrapment and subsequent activation. The recently reported autophagy-dependent extracellular delivery of TF in NETs further supports the involvement of neutrophils in thrombosis. Herein, we seek to review novel data regarding the role of neutrophils in thrombosis, emphasizing the implication of TF and NETs.

Keywords: neutrophil extracellular traps, thrombosis, tissue factor, neutrophil, coagulation cascade

Probably diagnosis:

- **Deficiency of TF-positive neutrophil (CD142)**
- Defenite treatment for neutropenia & coagulation disorder severity:
 - **Allogenic HSCT**



باتشکر از توجه شما

